چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| حسن دیانت مقدم | اول |
| مصطفی خلیلی | دوم |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Keywords: Hematopoietic stem cells; Graft-versus-host disease; Blood Transfusion. |
| خلاصه مقاله | Background Hematopoietic stem cell (HSC) transplantation (HSCT) used to treat a variety of disorders. HSCT reduced risk of graft-versus-host disease (GvHD) and need for post-transplant immunosuppressive drugs. Before HSCT, antigen and allele matching of donor and recipient must be performed. Future Directions Nowadays two collection protocols are available: continuous Mononuclear Cell Collection (cMNC) and MNC, which former is more efficient in unrelated donors and donors with low pre-apheresis peripheral HSC count. Risk of adverse events/effects and G-CSF administration are lower in children donors for peripheral blood SC collection; a promising avenue about donor safety that benefit from pediatric donors. GvHD will alleviated by reducing pretransplantation routine RBC transfusion, simultaneously HSC-organ transplantation, using blood redox state biomarker and suppressing signaling associated chronic GvHD pathogenesis. Pre-transplantation cytomegaloviruspositive patients, higher ferritin and busulphan level experienced a higher risk of poorer outcomes, while higher absolute lymphocyte count and increased albumin level associated with improved outcomes. The technically demanding, being expensive, no correlation between numbers of storage days at 4 °C and viability after storage during cryopreservation of HSCmay could be improved using non-cryopreserved PBSC. Genetic HSC disorders could be treated with converting haemogenic endothelium into functional HSC via recovering specific transcription factors. Applying genome-editing technologies specially clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 nuclease may widen the opportunity for introducing precise changes in HSC. Conclusion cMNC collection and non-cryopreserved PBSC storage are more efficient and cost-effective methods. GvHD could be improved by controlling routine RBC transfusion and signaling of GvHD pathogenesis. Frequently HSCT could be reduced via applying CRISPR-based system. Simple blood tests better used for assaying occurred risks in patients receiving myeloablative allogeneic HSCT. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Mini oral abstract.pdf | 1398/09/10 | 187050 | دانلود |
| Mini oral-licence.pdf | 1398/09/10 | 567841 | دانلود |
